October 2004

The US Food and Drug Government (FDA) approved Cymbalta (duloxetine hydrochloride) capsules for the organization of the pain associated with diabetic peripheral neuropathy.
This selective serotonin and norepinephrine reuptake inhibitor is the position drug specifically approved for this denotation.

This month’s upright reviews FDA new mathematical product approvals and labeling changes for:

Antidepressants

Cymbalta (duloxetine) Capsules

Antihistamines

Clarinex (desloratadine) Syrup

Illness Hormones

Saizen (somatropin [rDNA origin]) for Subcutaneous Intromission

Opioid Analgesics

Palladone (hydromorphone hydrochloride extended-release) CapsulesGrade 1 of 5
Jane S.
Ricciuti, RPh, MS, Administrator Editor program, AdComm Bulletin, and Programme Managing director, U.S.
Regulatory Affairs/IDRAC, Liquent, Inc., Frederick, Maryland.
This is a part of article October 2004 Taken from "Generic Clarinex (Desloratadine) Page" Information Blog